The epidemiology and etiology of invasive fungal infections have changed over recent decades. Mold infections are more fre¬quently encountered in association with increasing numbers of immunocompromised patients, and molds other than Aspergillus fumigatus, including species not previously recognized as patho¬gens, have emerged [1, 2]. The appearance of organisms, such as the Fusarium species and the Zygomycetes, with variable sus¬ceptibilities to conventional antifungal agents underscores the importance of correct identification [3].